Rubius Therapeutics

General Information
Business:

 

We are pioneering the development of a new class of medicines, Red Cell Therapeutics, or RCTs. Based on our vision that human red blood cells are the foundation of the next significant innovation in medicine, we have designed a proprietary platform to genetically engineer and culture RCTs that are selective, potent and ready-to-use cellular therapies.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 83
Founded: 2013
Contact Information
Address 325 Vassar Street, Suite 1A, Cambridge, MA 02139, US
Phone Number (617) 679-9600
Web Address http://www.rubiustx.com
View Prospectus: Rubius Therapeutics
Financial Information
Market Cap $1604.0mil
Revenues $0 mil (last 12 months)
Net Income $-54.5 mil (last 12 months)
IPO Profile
Symbol RUBY
Exchange NASDAQ
Shares (millions): 10.5
Price range $23.00 - $23.00
Est. $ Volume $241.5 mil
Manager / Joint Managers J.P. Morgan/ Morgan Stanley/ Jefferies/ Leerink Partners
CO-Managers -
Expected To Trade: 7/18/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change